The Latest Breaking News from UHS

Universal Health (UHS) reported robust financial results in the last quarter and raised its full-year outlook. The company's widespread operations, reputation, and high profitability continue to drive growth. So, let’s analyze whether it is the right time to buy, sell or hold UHS before its earnings. Read more to find…

Universal Health Services has substantially outperformed the S&P 500 over the past year and analysts remain moderately bullish about the stock’s prospects.

Summary Universal Health Services (UHS) shows strong technical indicators with 88% buy signals, 79.75% gain in the last year, and a Trend Seeker buy signal. UHS operates acute care hospitals and behavioral health facilities, with a market cap of $15.34 billion and a P/E ratio of 16.74. Analysts offer mixed...

Despite Universal Health Services’ outperformance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

The youngster was diagnosed with pelviureteric junction obstruction

Universal Health Services is all set to announce its second-quarter results this month, and Wall Street analysts predict a solid double-digit earnings growth.

Known as gastro-oesophageal reflux disease, the condition occurs when contents from the stomach flow back into the oesophagus the stomach.

ELF Beauty leads this weekend's watchlist of five stocks near buy points, including four consumer plays with durable demand trends.

Apple, Nvidia, Microsoft fueled the Nasdaq, but the market is increasingly split. Tesla has a new base, with caveats. Meta is among seven actionable stocks.

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

Experts at University Hospital Southampton took just 30 minutes to fit the Aveir VR leadless pacemaker